EGFR and neoplasm: Over the past decade, the scientific community focused on different mechanisms found to be responsible for the development of therapy resistance, such as genetic heterogeneity and activation of alternative survival pathways.2 Despite the availability of a large repertoire of new targeted therapeutics, there are not many options to treat patients with chemoresistant tumours, particularly if associated with activation of the signal pathway of rat sarcoma (RAS) or epidermal growth factor receptor (EGFR) resistance.